The top drugs facing cuts under Pelosi's pricing plan

The cancer drugs Revlimid, Keytruda and Opdivo, along with diabetes treatments Januvia and insulin would likely be among the medicines subject to Medicare price negotiation if a leading House proposal were to become law.